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HEART FAILURE SYNDROME 
Heart failure is a clinical syndrome characterized by symptoms and signs caused by structural or functional 
abnormalities of the heart. Typical symptoms are breathlessness, ankle swelling and fatigue. Typical signs are 
increased jugular venous pressure, third heart sound, peripheral edema and pulmonary crackles, however the 
condition can be present in the absence of these findings. It is important to address the underlying cause of 
heart failure, as the specific pathology determines choice of treatment. Common causes of heart failure are 
ischemic heart disease, dilated cardiomyopathies, valvular lesions, atrial fibrillation and hypertension. The 
toxic impact of chemotherapy and high levels of alcohol consumption can also lead to systolic left ventricular 
failure.1,2 Diabetes accelerates atherosclerosis and often leads to hypertension, but it is still debated whether 
diabetes causes a specific cardiomyopathy. Some data suggest that type 2 diabetes and hyperinsulinemia 
promote a “diabetic cardiomyopathy”.3 
 
The management of cardiovascular disease has undergone much change in recent years in general; notably 
recent advances in the management of acute coronary syndromes have significantly reduced both short-term 
and long-term mortality.4 This has led to increased survival, and thus, it could be argued, an increasing number 
of individuals with myocardial damage at risk of developing heart failure. The medical and device treatment of 
patients with established heart failure has also improved considerably, reducing both morbidity and 
mortality.5-8 Both changes are thought to have led to an increase in prevalence of heart failure. Thus, heart 
failure has become one of the most common cardiovascular diseases in the Western world. Epidemiological 
data show a prevalence of heart failure of 2%; and among individuals above 75 years, nearly 10% suffer from 
heart failure.9 Notably, the prevalence is even higher in patients with diabetes.10,11 Conversely, the prevalence 
of diabetes is very high in patients with heart failure with estimates of up to 40% in patients hospitalized with 
worsening symptoms.12,13 
EPIDEMIOLOGY OF HEART FAILURE AND DIABETES 
Compared with other cardiovascular events, observational data reveal a frequent occurrence of heart failure 
in patients with diabetes.14,15 The incidence of hospital admission for heart failure in 65,619 patients with type 
2 diabetes treated with insulin exceeded both myocardial infarction and stroke.16 Heart failure also appears to 
be the most common complication in several clinical outcome trials, especially in patients with diabetes and 
nephropathy.17,18 This is emphasized by the Irbesartan Diabetic Nephropathy Trial in which hospitalization for 
heart failure was the most frequent cardiovascular event, despite exclusion of patients with heart failure at 
baseline.17 The prevalence of heart failure in individuals with diabetes is also high, with one estimate of 
approximately 12%.10 Furthermore, heart failure in diabetes is associated with very poor outcomes and huge 
healthcare expenses.11,19 Once heart failure develops in individuals with diabetes mellitus, the outlook is grim 
with as much as a 10-fold higher mortality, compared to people with diabetes without heart failure, and a 5-
year survival rate of only 12.5%.11 Although more recent data have shown a better prognosis with a 3-year 
mortality of 40%,20 these findings highlight the clinical importance of the combination of heart failure and 
diabetes. Fortunately, the response to therapy for heart failure is similar in patients with and without 
diabetes,21,22 and is standardized in evidence-based international guidelines.1,2 
 
MANAGEMENT OF DIABETES MELLITUS IN HEART FAILURE 
While observational data suggest an association between lower glucose and less risk of macrovascular disease, 
randomized controlled trial data are generally not supportive.23 The one exception is the extended follow-up 
of the UK Prospective Diabetes Study (UKPDS), which studied patients with newly diagnosed diabetes, and 
showed a 16% reduction in the risk of heart failure per 1% absolute decrease in HbA1c.24 Other large-scale 
randomized controlled trials investigating the effect of more versus less intensive glycemic control, including 
The Action to Control Cardiovascular Risk in Diabetes (ACCORD), the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) and the Veterans Affairs Diabetes 
Trial (VADT), did not report a reduced risk of heart failure25-27, and neither did extended follow-up of VADT 
show a reduction in new or worsening heart failure.28 Indeed, some glucose-reducing agents are associated 
with either increased risk of developing heart failure or caused further deterioration of existing heart failure.29 
This is a major concern, especially in light of the absence of hospital admissions for heart failure as a 
prespecified component of primary composite cardiovascular outcomes in most large-scale trials investigating 
glucose-lowering agents. Furthermore, the optimal level of glycemic control in heart failure is uncertain, with 
some evidence suggesting that tight glycemic control may be associated with poorer outcomes in heart 
failure, possibly because of a cardiovascular risk related to hypoglycemia.30 Thus, how best to achieve glycemic 
control in patients with diabetes and heart failure remains an important and yet unanswered clinical question. 
Below, we will summarize the main findings from key clinical outcome trials, and discuss the potential 
mechanisms of benefit and harm of different glucose-lowering agents in heart failure. 
 
PHYSICAL TRAINING AND WEIGHT LOSS 
By reducing weight and blood pressure and perhaps by improving insulin sensitivity and other cardiovascular 
risk factors, regular exercise might be expected to reduce the risk of developing heart failure in patients with 
type 2 diabetes mellitus. However, in the one large prospective randomized trial testing this hypothesis, the 
Action for Health in Diabetes (Look-AHEAD) trial, carried out in 5,145 overweight or obese adults with type 2 
diabetes mellitus, an intensive lifestyle intervention promoting weight loss through decreased caloric intake 
and increased physical activity (intervention group) failed to improve cardiovascular outcomes compared to 
standard treatment. The primary outcome was a composite of death from cardiovascular causes, nonfatal 
myocardial infarction, nonfatal stroke, or hospitalization for angina during a maximum follow-up of 13.5 years 
and this was not reduced by the lifestyle intervention (hazard ratio [HR] = 0.95; 95% CI: 0.83 - 1.09). However, 
there was a trend towards a reduction in episodes of heart failure (99 versus 119 episodes, respectively) but 
this was not significant (HR = 0.80; 95% CI 0.61 - 1.04).31 
In patients with established heart failure and diabetes, regular exercise is thought to be beneficial by helping 
improve insulin sensitivity. By reducing blood pressure, cardiac hypertrophy, and left atrial volume, exercise 
and weight loss might be especially beneficial in patients with heart failure and preserved ejection fraction 
(HFpEF).32 Two clinical trials provide data on the effects of exercise in patients with both diabetes and heart 
failure. One study in patients with heart failure and reduced ejection fraction (HFrEF) suggested that exercise 
improved ejection fraction but was too small to provide robust evidence (N=42).33 In the only large trial 
examining the effect of regular exercise on outcomes in heart failure, the Controlled Trial Investigating 
Outcomes of Exercise Training (HF-ACTION), heart failure patients with and without diabetes (N=2331) were 
randomized to aerobic exercise on top of usual care, or usual care alone, and exercise was shown to reduce 
the secondary composite endpoint of cardiovascular mortality or hospitalization due to heart failure after 
adjustment for prognostic baseline variables (HR = 0.85; 95% CI: 0.74 - 0.99).34 Importantly, there was no 
interaction between baseline diabetes status and the benefits of exercise training.35 The patients in HF-
ACTION had HFrEF, and it is unknown whether patients with diabetes and HFpEF might benefit from exercise. 
The only low quality evidence comes from one small-randomized study of caloric restriction and exercise 
training in 100 severely obese HFpEF patients with (N=35) and without (N=65) diabetes which suggested that 
these interventions led to both weight loss and improved functional capacity.36  
 
ALPHA-GLUCOSIDASE INHIBITORS 
Alpha-glucosidase inhibition lowers body weight and triglycerides. The efficacy and safety of two drugs in this 
class has recently been tested in randomized, placebo-controlled, clinical trials. In the first, the Alpha-
glucosidase-inhibitor Blocks Cardiac Events in Patients with Myocardial Infarction and Impaired Glucose 
Tolerance (ABC) trial, patients with impaired glucose tolerance and coronary heart disease and a LVEF > 40% 
were randomized to placebo or voglibose. The original intent was to enroll approximately 3000 patients but 
the trial was stopped early because an interim analysis of outcomes in the first 870 participants suggested a 
low probability of a positive outcome i.e. the trial was terminated for futility. Only 12 patients were 
hospitalized for heart failure during a follow-up period of 24 months.37 The much larger Acarbose 
Cardiovascular Evaluation (ACE) trial randomized 6522 patients with coronary heart disease and impaired 
glucose tolerance to either acarbose or placebo. After a median follow-up of 5 years there was no difference 
in the primary five-point composite outcome of cardiovascular death, non-fatal myocardial infarction, non-
fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure (HR = 0.98; 95% CI: 
0.86–1.11). There were 65 hospitalizations for heart failure in the acarbose group and 73 in the placebo group 
(HR = 0.89; 95% CI 0.63–1.24).38 
There are few data from studies conducted in patients with heart failure. A small non-randomized and 
underpowered study investigated the effect of 24 weeks of treatment with open-label voglibose on 
cardiovascular function in 30 patients with dilated cardiomyopathy and impaired glucose tolerance. Voglibose 
treatment was associated with reduced left ventricular dimensions, NYHA functional classification, and plasma 
BNP levels, compared with control subjects.39 Clearly, the safety of alpha-glucosidase inhibitor treatment in 
patients with diabetes and chronic heart failure has not been adequately evaluated and should be in light of 
its frequent use in Asian countries. 
 
BIGUANIDES (METFORMIN) 
There is a widely held view that metformin is cardioprotective, and proposed mechanisms of action include 
direct myocardial effects, and indirect effects related to weight loss and improved insulin sensitivity. The 
evidence for cardio-protection is, however, weak in general and non-existent for heart failure in particular. 
The United Kingdom Prospective Diabetes Study (UKPDS) randomized 753 overweight (>120% ideal 
bodyweight) patients with newly diagnosed type 2 diabetes and raised fasting plasma glucose (FPG; 6.1–15.0 
mmol/L) despite 3 months of dietary intervention to conventional treatment, primarily with diet alone 
(n=411), or an intensive blood-glucose control approach with metformin, aiming for a FPG below 6 mmol/L 
(n=342). Median follow-up was 10.7 years. There were few episodes of heart failure and these did not differ 
between treatment groups.40 Long-term follow-up of UKPDS has been published recently but heart failure was 
not reported.41  
There is even less evidence about the potential actions of metformin in patients with established heart failure 
(as opposed to preventing incident heart failure). At present, the largest randomized study to evaluate the 
effect of metformin in heart failure patients randomized only 60 insulin resistant subjects to treatment for 
four months. Metformin did not improve the primary endpoint cardiopulmonary exercise.42 
Consequently, we have to rely on observational studies to examine associations between metformin use and 
clinical outcomes in patients with heart failure, with the recognized and significant limitations of such studies. 
Metformin use seems to be associated with better outcomes than treatment with other glucose lowering 
treatments in several observational studies. First, a Canadian cohort study examined outcomes in 1,833 
patients with diabetes and incident heart failure. The study demonstrated that use of metformin either as 
monotherapy or combined with a sulfonylurea was associated with a lower 1-year mortality compared to 
sulfonylurea treatment alone (HR = 0.83; 95% CI: 0.70 - 0.99).43 The use of metformin in diabetic patients with 
heart failure has been associated with better outcomes, including hospitalization for heart failure in several 
other cohort studies.44-50 Although metformin use may be associated with both lower mortality and morbidity 
in heart failure, compared with other treatments, it is important to stress the limitations of observational 
studies, principally due to confounding. For example, it is possible that the prescription of metformin is just a 
marker of less severe disease, but despite the lack of data from randomized trials, these observational 
analyses have led to the view that metformin is safe in heart failure in patients with eGFR above 30 ml/min. 
However, it is also important to point out that metformin can potentially cause lactic acidosis, and should not 
be used in patients with severe disease such as those who have become acutely decompensated or those with 
renal failure. Caution should also be exercised when administrating iodine contrast agent, during perioperative 
periods, and in situations with possible hypoxic states like respiratory failure, myocardial infarction, shock or 
sepsis. 
Ideally, a large randomized clinical trial is required to investigate the effects of metformin treatment on 
mortality and morbidity in heart failure patients, but one attempt to conduct such a trial failed because it 
appears that physicians did not accept that there was equipoise and preferred to prescribe metformin, rather 
than randomize patients.51 
 
SULFONYLUREAS 
Sulfonylureas increase insulin release thereby reducing blood glucose. However, the increases in insulin levels 
may cause hypoglycemia and weight gain. These actions could potentially exacerbate heart failure. The 
University Group Diabetes Program (UGDP) was the first large randomized trial in patients with type 2 
diabetes mellitus conducted between 1961 and 1975. One treatment group received a fixed dose of the 
sulfonylurea tolbutamide (1.5 g daily in divided dose, regardless of plasma glucose response) and there were 
two insulin groups and a placebo group (a phenformin group was added later). An interim analysis of this trial 
in 1969 revealed a statistically significant excess of cardiovascular deaths in the tolbutamide arm, leading to 
premature discontinuation of this arm of the trial.52 The number of heart failure events were not reported, 
only the number of patients receiving heart failure medication at any time after randomization (tolbutamide = 
22 vs. placebo = 13, p=0.13), but the type of drug and doses were not reported.53 
In the united Kingdom Prospective Diabetes Study (UKPDS), 3867 newly diagnosed patients with type 2 
diabetes, who had a fasting plasma glucose (FPG) concentrations of 6.1–15.0 mmol/l despite 3 months 
treatment with diet, were randomly assigned to intensive treatment with a sulphonylurea (chlorpropamide, 
glibenclamide, or glipizide; N=1234) or with insulin (N=911), or conventional treatment with diet (N=896). The 
aim in the intensive group was FPG less than 6 mmol/l. There were 48 new cases of heart failure in the 
sulfonylurea group compared with 62 in the conventional therapy group.54 
As with metformin, the evaluation of the safety of sulfonylureas as a treatment for diabetes in patients with 
established heart failure has relied mainly on observational data. A retrospective cohort study of 16,417 
patients with type 2 diabetes and heart failure found no evidence that mortality was higher in individuals 
treated with a sulfonylurea compared with other glucose lowering drugs (HR = 0.99; 95% CI: 0.91 - 1.08).44 
However, follow-up in this study was limited to one year and treatment with sulfonylurea was compared to 
other glucose-lowering agents that in themselves may worsen heart failure, including insulin and 
thiazolidinedione. In another study, Eurich et al. identified 1,833 patients with incident heart failure who were 
treated with an oral glucose-lowering agent. The mean follow-up time was 2.5 years. Mortality, as well as the 
rate of hospitalization for heart failure, was higher in patients taking sulfonylurea monotherapy compared 
with metformin (metformin versus sulfonylurea HR = 0.83; 95% CI: 0.70 - 0.99).43 A Danish registry study with 
more than 10,000 patients reported a similar finding.48 Thus, the existing literature indicates that the safety of 
sulfonylureas in heart failure is uncertain, principally due to the reliance on observational studies and lack of 
randomized controlled trials.  
 
INSULIN 
Insulin may have positive inotropic effects on myocardial tissue and improve other hemodynamic measures, 
but may also cause sodium retention, weight gain and possibly edema which are likely to be undesirable in 
heart failure. Sodium retention is dose dependent and present even in physiologic concentrations of insulin.55 
Fluid retention due to insulin is usually mild, but it could potentially increase the severity of heart failure, and 
several case reports of new-onset heart failure in patients who started insulin treatment have been published. 
However, in the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial 12,537 patients with 
impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes and cardiovascular risk factors were 
randomized to insulin or standard care alone. Insulin had a neutral effect on the composite outcome including 
death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, cardiovascular 
revascularization procedures, or hospitalization for heart failure (HR = 1.04; 95% CI: 0.97–1.11).56 There were 
310 patients hospitalized with heart failure in the insulin group and 343 in the placebo group (HR 0.90, 0.77–
1.05; p=0.16). These findings are somewhat reassuring, but patients in the ORIGIN trial did not all have 
diabetes or had diabetes for a very short time, and the risk of heart failure rises with increasing age and 
duration of diabetes.  
Only one small and short-term randomized clinical trial has evaluated the effect of insulin in patients with 
diabetes and established heart failure. This trial randomized 40 patients with type 2 diabetes, reduced left 
ventricular systolic function and HbA1c > 7.5% to optimized diabetes treatment including insulin use, or no 
optimization for four months. The primary outcome was defined as changes in left ventricular contractile 
reserve capacity from baseline to follow-up. The study showed no impairment of cardiac function and no 
patients were hospitalized for heart failure during the study period.57 On the other hand, in a variety of 
retrospective analyses of trials and in observational studies, treatment with insulin has been consistently 
associated with worse outcomes than no treatment with insulin. As with all observational studies it is 
impossible to know whether these findings reflect “cause and effect” (i.e. that insulin is harmful) or 
confounding, especially as insulin treated patients are usually older with longer-standing diabetes, more 
advanced cardiovascular and renal disease and other adverse prognostic characteristics.58-60 The bottom line is 
that the existing data available to the clinical community are insufficient to exculpate insulin from causing 
worse outcomes in patients with heart failure. If it proves necessary to start insulin in a patient with heart 
failure, it is important to monitor the patient for signs of fluid retention. 
 
THIAZOLIDINEDIONES (GLITAZONES) 
Thiazolidinediones (glitazones) enhance insulin sensitivity by increasing the efficiency of glucose transporters. 
On the other hand, these agents also cause weight gain, edema and fractures. The mechanisms underlying 
edema are unknown, but may include activation of collecting duct sodium channels, and proximal tubular 
sodium channel, as well as peripheral arteriolar vasodilation.61-63 The clinical manifestations are an essential 
part of the heart failure syndrome, and robust data suggest an increased risk of incident heart failure in 
patients with pre-diabetes as well as type 2 diabetes treated with thiazolidinedione.64 This was exemplified by 
the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) trial in 
which 4,447 patients with type 2 diabetes and dysglycemia on metformin or sulfonylurea monotherapy were 
randomized to either add-on rosiglitazone or a combination of metformin and sulfonylurea.65 Patients were 
followed over an average period of 5.5 years, and rosiglitazone treatment was associated with a doubled risk 
of fatal or non-fatal heart failure events (61 versus 29; HR = 2.10; 95% CI: 1.35-3.27).66 There are three large 
trials with pioglitazone in patients with diabetes and/or impaired glucose tolerance and these have shown a 
less striking increase in risk of heart failure (and a reduction in athero-thrombotic events).67-69 
There are few data from studies in patients with established heart failure. Only two small and short-term 
randomized clinical trials have investigated the effect of thiazolidinediones in heart failure patients with type 2 
diabetes. The primary outcome was change in LVEF. There was no negative effect on left ventricular function 
in either study; however, thiazolidinedione treatment were associated with an increase in B-type natriuretic 
peptide (BNP), a marker of increased left ventricular wall stress and predictor of adverse cardiovascular 
outcomes.70,71 Dargie et al. investigated the effect of rosiglitazone, compared to placebo, given for 52 weeks in 
224 patients with type 2 diabetes and HFrEF. Rosiglitazone treatment was associated with a tendency towards 
increased risk of all-cause mortality and hospitalization due to heart failure (HR = 1.28; 95% CI: 0.51-3.21).70 
Giles et al. investigated the effect of pioglitazone in a similar way. In total, 300 patients with diabetes and 
HFrEF were randomized to 12 months’ treatment with pioglitazone or glyburide; treatment with pioglitazone 
was associated with worsening heart failure symptoms as well as a larger number of hospitalizations for heart 
failure.71 The US Food and Drug Administration has given thiazolidinediones a “black box” warning in relation 
to use in acute or symptomatic chronic heart failure patients.72 
 
INCRETIN THERAPIES  
The incretins are a family of gut hormones produced by enteroendocrine cells. The two main molecules of 
interest are glucagon-like peptide-1 (GLP-1) and the gastric inhibitory hormone (GIP). GLP-1 hormone is 
secreted in response to food intake; it decreases glucagon excretion and increases insulin levels.73 The 
protease dipeptidyl peptidase-4 (DPP-4) rapidly decomposes native GLP-1. Pharmacological inhibitors of DPP-4 
and GLP-1 receptor agonists with longer bioavailability have been developed.74 
 
DPP-4 INHIBITORS  
DPP-4 has several postulated substrates in addition to GLP-1, including BNP, erythropoietin, glucagon, 
vasoactive intestinal peptide, and vasostatin.75 Thus, DPP-4 inhibition could affect pathways involving cardiac 
signaling, collagen turnover, and the sodium hydrogen exchanger in the renal proximal tubule.76 
Clinical outcomes have been reported in three randomized controlled trials using of DPP-4 inhibitors. The 
Saxagliptin Assessment of vascular Outcomes Recorded in Patients with Diabetes Mellitus – Thrombolysis 
in Myocardial Infarction 53 (SAVOR-TIMI 53) trial was the first large-scale outcome trial to investigate the 
cardiovascular safety of a DPP-4 inhibitor in 16,492 patients with type 2 diabetes and either a high risk of 
cardiovascular disease or known cardiovascular disease. The trial did not show a reduction in the primary 
composite outcome of cardiovascular death, myocardial infarction or ischemic stroke. Surprisingly, there was 
an increase in the risk of hospitalization for heart failure with saxagliptin, compared with placebo (289 versus 
228 patients hospitalized, respectively; HR = 1.27; 95% CI: 1.07 - 1.51).77 Subsequent analysis showed that the 
risk of heart failure was highest in patients with elevated BNP, a history of heart failure and chronic kidney 
disease.78 Whether this completely unexpected finding reflected the play of chance, or, if real, was a DPP-4 
inhibitor class effect (or even an issue for other incretin-based therapies including GLP-1 receptor agonists) or 
a drug-specific hazard was unknown at that point, but emphasized the importance of heart failure as an 
outcome in trials testing new therapies for diabetes. Therefore, the outcomes of subsequent trials with DPP4-
inhibitors were eagerly awaited after SAVOR-TIMI 53. In the Examination of Cardiovascular Outcomes with 
Alogliptin versus Standard of Care (EXAMINE) trial 5,380 patients with type 2 diabetes and recent acute 
coronary syndrome were randomized to receive alogliptin or placebo. There was a non-significant trend to an 
increase in heart failure hospitalization with alogliptin compared to placebo (106 versus 89 case, respectively; 
HR = 1.07; 95% CI: 0.79 – 1.46).79 However, in the Trial to Evaluate Cardiovascular Outcomes after Treatment 
with Sitagliptin (TECOS), no such risk was seen with sitagliptin. TECOS randomized 14,671 patients with type 2 
diabetes and a history of major coronary artery disease, ischemic cerebrovascular disease, or atherosclerotic 
peripheral arterial disease to DPP-4 inhibitor therapy or placebo.80 There were a similar number of patients 
hospitalized with heart failure in the sitagliptin group (228 cases) and placebo group (229 cases); HR = 1.00; 
95% CI: 0.83 - 1.20. There were 2643 patients with heart failure at baseline in TECOS and the treatment effect 
in this subgroup was similar to that in the trial overall; however the phenotype of patients with heart failure at 
baseline (and occurring following randomization) was not defined. While TECOS may have been reassuring, 
none of these studies included a substantial number of patients with a diagnosis of heart failure at baseline, 
leaving uncertainty about the safety of DPP4-inhibitors in patients with established heart failure. The US Food 
and Drug administration has issued a safety communication concerning saxagliptin and alogliptin stating that 
health care professionals should consider discontinuing both drugs in patients who develop heart failure 
(http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm). 
As with the other blood glucose-lowering drugs discussed so far, there are few data on the use of DPP-4 
inhibitors specifically in patients with established heart failure. The effects of alogliptin, saxagliptin and 
sitagliptin on heart failure hospitalization in the subgroups of patients with prevalent heart failure at baseline 
in EXAMINE, SAVOR-TIMI 53 and TECOS are shown Table 1, but, as pointed out, the heart failure phenotype in 
these patients was not characterized. The Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) 
investigated the effect of vildagliptin on cardiac function in 254 patients with type 2 diabetes and HFrEF. The 
study met the primary endpoint of statistical non-inferiority in terms of change in LVEF, and no difference in 
time to any first cardiovascular event between the two groups was observed (35 events in the vildagliptin 
group vs. 31 in the placebo group). However, there were 11 deaths from any cause in the vildagliptin arm and 
four deaths in the placebo arm.81 Although the study was not powered to evaluate hard endpoints, it 
highlights the uncertainty of DPP4-inhibitor use in patients with chronic heart failure. 
 
GLP-1 RECEPTOR AGONISTS 
The effect of GLP-1 receptor agonists on glucose lowering and weight loss exceeds the effects of DPP4-
inhibitors. Substances can be divided in to two groups according to their structural basis (exendin or GLP-1 
related) and their half-life: 
 I. Short acting (terminal half-life <24 hours)/exendin-4 based: exenatide 
II. Long acting (>24 hours)/exendin-4 based: extended duration exenatide  
III. Short-acting (<24 hours)/GLP-1 based: lixisenatide, liraglutide  
IV. Long-acting (>24 hours)/GLP-1 based: dulaglutide, albiglutide and semaglutide 
 
The effect of the short-acting GLP-1 analogue lixisenatide on cardiovascular outcomes was tested in the 
Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial. Patients with type 2 diabetes and an acute 
coronary syndrome (N=6,068) within 15 to 180 days were randomized to receive lixisenatide or placebo in 
addition to standard of care. Lixisenatide had a neutral effect on the primary and secondary outcomes, 
including hospitalization for heart failure (122 versus 127 patients hospitalized; HR = 0.96; 95% CI: 0.75 - 
1.23).82 The effect of the longer-acting GLP-1 analogue liraglutide was tested in the Liraglutide Effect and 
Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. LEADER included patients 
(N=9340) with type 2 diabetes and established cardiovascular disease or cardiovascular risk factors, and 14% 
of patients in LEADER had a history of NYHA functional class II or III heart failure at enrolment (probably a 
mixture of HFrEF and HFpEF).83 Liraglutide reduced the risk of the primary composite endpoint (HR = 0.87; 
95% CI: 0.78 - 0.97) as well as cardiovascular and all-cause mortality; there was also a nominally statistically 
significant reduction in myocardial infarction. The risk of heart failure hospitalization, however, did not differ 
between groups (218 versus 248 patients hospitalized; HR = 0.87; 95% CI: 0.73 - 1.05).84 In the subgroup of 
1305 patients with heart failure at baseline the treatment effect of liraglutide was consistent with that 
observed in the trial overall; however the phenotype of patients with heart failure at baseline (and occurring 
following randomization) was not defined. 
Consistent with these findings, a very long-acting GLP-1 agonist, semaglutide, was shown in the Trial to 
Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes 
(SUSTAIN-6; N=3297) to reduce the same combined primary cardiovascular endpoint (HR = 0.74; 95% CI: 0.58 - 
0.95) although without a statistically significant effect on mortality or myocardial infarction (but with a 
reduction in stroke). Semaglutide did not reduce the risk of heart failure hospitalization (HR = 1.11; 95% CI: 
0.77 - 1.61).85  
Most recently, the Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) tested an alternative long-
acting GLP-1 receptor agonist, with a different structural basis than liraglutide and semaglutide, but similar to 
that of lixisenatide (exenatide and lixisenatide are exendin-4 based). In EXSCEL, 14.572 patients were 
randomized equally to exenatide once weekly or placebo. There was a trend to a reduction in the primary 
composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke with 
exenatide (HR 0.91, 0.83 - 1.00; p=0.061 for superiority) and a nominally statistically significant reduction in 
all-cause death. There were 219 patients hospitalized with heart failure in the exenatide group and 231 in the 
placebo group (HR 0.94, 0.78-1.13).86 In keeping with all other large cardiovascular outcome trials in patients 
with diabetes, none of these trials reported data on left ventricular ejection fraction (LVEF).  
Once again, there are few data about the effects of GLP-1 receptor agonists in patients with established heart 
failure.  The effects of lixisenatide and liraglutide on heart failure hospitalization in the subgroups of patients 
with prevalent heart failure at baseline in ELIXA and LEADER are shown in Table 1, but, as pointed out, the 
heart failure phenotype in these patients was not characterized. The Functional Impact of GLP-1 for Heart 
Failure Treatment (FIGHT) study and the Effect of Liraglutide on Left Ventricular Function in Stable Chronic 
Heart Failure Patients (LIVE) study investigated the effects of liraglutide in more than 500 patients with HFrEF. 
Neither of these studies showed an effect on LVEF, but they raised concerns about the safety of liraglutide in 
patients with HFrEF.87,88 In LIVE, liraglutide increased heart rate by 7 beats per minute compared with placebo 
and there were more serious cardiac events (composite of death or hospitalization for any cardiovascular 
event). A total of 12 patients in the treatment group and 3 patients in the placebo group experienced a serious 
cardiac event (HR = 3.9; 95% CI: 1.1 - 13.8). The FIGHT study reported a trend towards more serious cardiac 
events in liraglutide-treated patients. This was notable for the combined endpoint of death and 
rehospitalization due to heart failure (liraglutide = 43 and placebo = 30, HR = 1.54; 95% CI: 0.97 - 2.46).87 
Although not powered to evaluate clinical outcomes, the results of these two studies demonstrate why 
outcome trials with diabetes drugs are needed specifically in patients with heart failure – it cannot be 
assumed that treatments will have the same safety profile in patients with heart failure as in those without. 
Furthermore, the effect of treatments may be very different in patients with HFrEF compared to HFpEF. 
 
SODIUM GLUCOSE TRANSPORT 2 RECEPTOR INHIBITORS 
Sodium glucose co-transport 2 receptor (SGLT2) is a low-affinity, high-capacity sodium glucose co-transporter 
thought to be exclusively located in the renal proximal tubule. SGLT2 is responsible for 90% of glucose 
reabsorption, and inhibition induces a decrease in blood glucose due to glycosuria. Secondary effects of SGLT2 
inhibition include a modest diuretic effect, weight loss, lowering of blood pressure and reduced levels of uric 
acid and triglycerides.89 The first cardiovascular outcome trial with a SGLT2 inhibitor to report, the 
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME), 
included 7,020 patients with type 2 diabetes and known cardiovascular disease. EMPA-REG OUTCOME showed 
a significant reduction in the primary composite outcome of cardiovascular death, non-fatal myocardial 
infarction or non-fatal stroke with empagliflozin (HR 0.86, 95.02% confidence interval 0.74 -0.99; p = 0.04 for 
superiority). This treatment benefit was mainly due to a relative-risk reduction of 38% in death from 
cardiovascular causes (HR = 0.62; 95% CI: 0.49 - 0.77). There was also a 35% relative risk reduction in 
hospitalization for heart failure (HR = 0.65; 95% CI: 0.50 - 0.85) with empagliflozin compared to placebo.90 It is 
noteworthy that this effect was independent of baseline treatment with anti-congestive medication and 
consistent in the subgroup of patients with heart failure at baseline (N= 706, again, without the phenotype 
defined). The findings from EMPA-REG have been supported by the CANagliflozin cardioVascular 
Assessment Study program (CANVAS) which consisted of two trials enrolling 10,142 participants with type 2 
diabetes and either established cardiovascular disease or with cardiovascular risk factors, randomized to 
receive canagliflozin or placebo. Overall, the findings of CANVAS were broadly similar to EMPAREG-OUTCOME 
with a 14% relative risk reduction in the same primary outcome in the canagliflozin group (HR 0.86, 0.75 to 
0.97; p = 0.02 for superiority). Although there was not a statistically significant reduction in cardiovascular 
mortality, there was a 33% relative risk reduction in hospitalization for heart failure (HR = 0.67; 95% CI: 0.52 - 
0.87), similar to that seen in EMPAREG-OUTCOME. The benefit of canagliflozin seemed to be consistent in the 
subgroup of 1461 patients with heart failure at baseline (not phenotyped) and possibly greater in participants 
treated with a diuretic at baseline.91 The mechanism or mechanisms by which SGLT-2 inhibitors reduce heart 
failure hospitalization are unknown; however, natriuresis and blood pressure reduction may be important, 
leading to a reduction in pre-load and afterload. Other suggestions include an improvement in myocardial 
metabolism as a result of the mild ketonemia caused by SGLT-2 inhibition (damaged myocardium may use 
ketones as a more metabolically efficient substrate) and a possible inhibition of sodium/hydrogen exchange in 
cardiomyocytes (potentially reducing intracellular calcium accumulation and risk of arrhythmias). 
There are no substantial completed trials in patients with established heart failure, so, to date we must rely on 
the subgroup analyses from EMPA-REG OUTCOME and CANVAS described above. The effects of empagliflozin 
on heart failure hospitalization in the subgroup of patients with prevalent heart failure at baseline in 
EMPAREG-OUTCOME is shown Table 1, but, as pointed out, the heart failure phenotype in these patients was 
not characterized. Fortunately, three large randomized outcome trials in patients with heart failure are 
underway. Two of these, with empagliflozin and dapagliflozin, are in patients with HFrEF (NCT03036124 and 
NCT03057977) and one, with empagliflozin, in HFpEF (NCT03057951).  
 
OTHER GLUCOSE LOWERING DRUGS 
Nateglinide 
The meglitinides (“glinides”) bind to an ATP-dependent K1 channel on the membrane of pancreatic beta cells 
in a similar manner to sulfonylureas and lead to a short-term increase secretion of insulin. The safety of 
nateglinide - in addition to lifestyle modification - was evaluated in the Nateglinide and Valsartan in Impaired 
Glucose Tolerance Outcomes Research (NAVIGATOR) trial.92 In total, 9306 participants with impaired glucose 
tolerance and either cardiovascular disease or cardiovascular risk factors received nateglinide (up to 60 mg 
three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo. Patients were followed for 
a median of 5.0 years and one co-primary outcomes was a composite of death from cardiovascular causes, 
nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Nateglinide did not reduce 
the incidence of the composite endpoint, and although hospitalizations for heart failure were numerically 
fewer, this reduction was not statistically significant (nateglinide 5 85 vs. placebo 5 100, HR, 0.85; 95% CI, 
0.64–1.14).93 
 
Bromocriptine 
Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, 
is a US Food and Drug Administration–approved treatment for type 2 diabetes mellitus. Taken in the morning, 
bromocriptine-QR is thought to cause an increase in central dopaminergic tone at the time of day it normally 
peaks in healthy individuals (this circadian peak linked to preservation and/or induction of normal insulin 
sensitivity and glucose metabolism). A total of 3,095 patients with type 2 diabetes were randomized 2:1 to 
bromocriptine-QR or placebo in conjunction with the patient’s usual diabetes therapy in a 52-week evaluation 
of cardiovascular and overall safety.94,95 As part of this assessment there was a pre-specified 
analysis of a composite cardiovascular endpoint of myocardial infarction, stroke, coronary revascularization, 
and hospitalization for angina or congestive heart failure, evaluated using modified intent-to-treat 
analysis.94,95 Fewer people experienced this end point in the bromocriptine-QR group compared with the 
placebo group: 37 (1.8%) vs. 32 (3.2%), respectively, HR 0.60 (95% CI 0.35–0.96). Subsequently, a composite 
including death from cardiovascular causes was reported: 39 (1.9%) 33 (3.2%), respectively, HR 0.61 (0.38 to 
0.97).94,95 There were 9 patients (0.4%) hospitalized for heart failure in the bromocriptine-QR group and 6 
(0.6%) in the placebo group. 
 
 
 
SUMMARY AND INTERPRETATION 
It is only in the past few years that, after decades of use, we are beginning to obtain evidence on the 
cardiovascular effects of glucose lowering drugs, although these recent data only apply to the newer agents 
and not to established therapies such as metformin and sulphonylureas. Notably, one class of treatment, the 
thiazolidinediones (glitazones) clearly increase the risk of developing heart failure and worsening of heart 
failure in patients with the syndrome. There is a similar concern about at least some DPP-4 inhibitors. While 
GLP-1 receptor agonists do not seem to increase the risk of developing heart failure, their safety and efficacy 
in patients with established heart failure is uncertain. Uniquely among all glucose lowering therapies, the 
SGLT-2 inhibitors reduce the incidence of heart failure in patients with type 2 diabetes and their safety and 
efficacy in patients with established heart failure are being extensively assessed in three new large 
mortality/morbidity outcome trials, setting a new benchmark for evaluation of the effects of new diabetes 
drugs on cardiovascular outcomes.  
What can we conclude on the basis of the currently available evidence? Table 1 summarizes what we know 
about outcomes with glucose lowering agents in relation to heart failure. Clearly, at present, it is not possible 
to make firm evidence-based recommendations about any treatment for diabetes in patients with HFrEF or 
HFpEF. Our tentative conclusions from the available data are that the SGLT-2 inhibitors seem to be the class of 
treatment least likely to be harmful and TZDs should be avoided.  
 
TABLES 
 
 PROactive RECORD EXAMINE SAVOR-
TIMI 53 
TECOS ELIXA LEADER SUSTAIN-6 EXSCEL EMPA-REG 
OUTCOME 
CANVAS ACE 
Time of 
completion 
2005 2009 2013 2013 2015 2015 2016 2016 2017 2015 2017 2017 
Drug studied Pioglitazone Rosiglitazone Alogliptin Saxagliptin Sitagliptin Lixisenatide Liraglutide Semaglutide Exenatide Empagliflozin Canagliflozin Acarbose  
Class TZD TZD DPP-4 I DPP-4 I DPP-4 I GLP-1 RA GLP-1 RA GLP-1 RA GLP-1 RA SGLT2-i SGLT2-i α-glucosidase 
inhibitor 
Participants (N) 5,238 4,447 5,380 16,492 14,671 6,068 9,340 3,297 14,752 7,020 10,142 6,522 
Trial duration 
(median) 
2.9 years† 5.5 years† 1.5 years 2.1 years 3.0 years 2.1 years 3.8 years 2.1 years 3.2 years 3.1 years 3.6 years† 5.0 years 
Prevalent HF % (N) N/A N/A 28 (1501) 13 (2105) 18 (2643) 22.4 (1358) 18 (1667)* 23.6 (777) 16.2 (2389) 10 (706) 14.4 (1461) 3.7 (243) 
Treatment effects on HF hospitalization in overall group and in those with prevalent HF 
HR overall (95% CI) 1.41 (1.10-
1.80) 
2.10 (1.35-
3.27) 
1.19 (0.9-
1.58) 
1.27 (1.07-
1.51) 
1.00 (0.83-
1.19) 
0.96 (0.75-
1.23) 
0.87 (0.73-
1.05) 
1.11 (0.77- 
1.61) 
0.94 (0.78- 
1.13) 
0.65 (0.50- 
0.85) 
0.67 (0.52-
0.87) 
0.89 (0.63-
1.24) 
HR prevalent 
HF (95% CI) 
N/A N/A 1.00 (0.71-
1.42) 
1.21 (0.99-
1.58) 
1.03 (0.77-
1.36) 
0.93 (0.66-
1.30) 
0.95 (0.71-
1.28) 
NR NR 0.75 (0.48-
1.19) 
NR NR 
 
TZD; thiazolidinedione, DPP-4 I; dipeptidyl peptidase-4 inhibitor, GLP-1 RA; glucagon-like peptide-1 analogue, SGLT2-i; sodium glucose co-transporter - 2 inhibitor, HF; heart failure. 
*14% (1305) NYHA class II and III; 18% (1667) NYHA class I-III 
† Mean
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